The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial

BACKGROUND: In a Phase II clinical trial, we reported the effectiveness and safety of a sandwich neoadjuvant treatment based on a modified oxaliplatin plus capecitabine (XELOX) regimen for locally advanced rectal cancer (LARC). The pathologic complete response (pCR) rate was 42.2%, and no patient pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yong-Hong, Wei, Jia-Wang, Chang, Hui, Xiao, Wei-Wei, Lin, Jun-Zhong, Cai, Mu-Yan, Cai, Pei-Qiang, Kong, Ling-Heng, Chen, Gong, Pan, Zhi-Zhong, Zeng, Zhi-Fan, Ding, Pei-Rong, Gao, Yuan-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188179/
https://www.ncbi.nlm.nih.gov/pubmed/30349369
http://dx.doi.org/10.2147/CMAR.S168573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188179/
https://www.ncbi.nlm.nih.gov/pubmed/30349369
http://dx.doi.org/10.2147/CMAR.S168573

Ejemplares similares